Titlebook: Biology and Treatment of Leukemia and Bone Marrow Neoplasms; Vinod Pullarkat,Guido Marcucci Book 2021 Springer Nature Switzerland AG 2021

救護(hù)車

Current and Emerging Therapies for Acute Myeloid Leukemia,topoietic cell transplantation with curative intent. Progress is also being made in the field of monoclonal antibodies targeting leukemia antigens and other immunotherapies and many such agents are currently under active investigation.

Expressly

Chronic Lymphocytic Leukemia (CLL): Biology and Therapy,luding those with . deletions/mutations who previously had a dismal outcome with conventional chemoimmunotherapy. Allogeneic HCT is a potentially curative option for selected younger patients with?multiply relapsed high-risk disease.

sphincter

沐浴

Die wichtigsten Kommunikationsmodellehypomethylating agents and hematopoietic cell transplantation (HCT) for higher risk disease. In this chapter, we review the classification, risk stratification, and optimal management of patients with MDS.

滔滔不絕的人

Advances in Diagnosis and Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndrom using the latest next generation sequencing technology can sequence an entire human genome within a few hours. Diagnosis and prognostication of hematologic neoplasms have moved from traditional histology and immunophenotyping to integration of cytogenetic and genomic alterations. Using illustrative

尾巴

Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma,decade with advances in sequencing and other molecular techniques. Besides recurrent chromosomal abnormalities detected by karyotyping or fluorescence in situ hybridization, these leukemias/lymphomas are characterized by a variety of mutations, gene rearrangements as well as copy number alterations.

預(yù)兆好

creditor

注入

Current Management and New Developments in the Treatment of ALL, treatment approaches to newly diagnosed as well as relapsed/refractory acute lymphoblastic leukemia (ALL) have changed. This chapter summarizes the newest treatment approaches in newly diagnosed T-cell and B-cell ALL, as well as the use of novel therapies for relapsed and refractory ALL.

Heresy

CML Chapter,myeloid leukemia (CML) [Hochhaus et al. in N Engl J Med 376:917–927, 2017]. The treatment of patients with CML has changed dramatically since the approval of imatinib and other TKIs. Before the TKI era, newly diagnosed patients would undergo HLA typing to try to identify a well-matched donor, and th